MINDACT Trial Findings On Agendia’s MammaPrint To Be Presented During AACR Annual Meeting 2016

IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announced today that results from the initial analysis of the primary objective of the EORTC 10041/ BIG 3-04 study “Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy” (MINDACT) will be presented at the AACR Annual Meeting 2016, April 16-20 in New Orleans, LA.

“Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy”

The study looked at the use of the company’s MammaPrint 70-Gene Breast Cancer Recurrence assay in diagnostic testing. MINDACT is a phase III, prospective, randomized controlled, clinical trial comparing the use of MammaPrint 70-gene assay with clinical-pathological criteria (current standard of care) for selecting early breast cancer patients who should not be treated with adjuvant chemotherapy, sponsored by European Organization for the Research and Treatment of Cancer and conducted under the Breast International Group umbrella.

“The MINDACT trial design is the optimal way to prove clinical utility on a genomic assay,” said Prof. Laura van ’t Veer, Chief Research Officer at Agendia and Leader, Breast Oncology Program, and Director, Applied Genomics at UCSF Helen Diller Family Comprehensive Cancer Center. “In this trial, MammaPrint was compared to the standard of care physicians use today, to decide what is the best treatment option for an early-stage breast cancer patient."

A press conference is scheduled for Monday, April 18 at 8:30 AM CDT and the presentation of results will take place soon after, during the Transformative Clinical Trials in Breast Cancer session from 10:30 AM to 12:30 PM CDT.

Professor Martine Piccart MD, PhD, one of the three principal investigators of MINDACT, will present the study. Professor Laura van ‘t Veer Ph.D, Leading Scientist and developer of the 70-gene signature, will also be available to answer questions about the trial design and the importance of its results. In addition, Mark Straley, Chief Executive Officer of Agendia, will also be available to answer questions.

Session Title: Transformative Clinical Trials in Breast Cancer
Session Type: Clinical Trials Plenary Session
Session Start/End Time: Monday, Apr 18, 2016, 10:30 AM -12:30 PM
Location: La Nouvelle Orleans Ballroom, Morial Convention Center
CT039: Primary analysis of the EORTC 10041/ BIG 3-04 MINDACT study: a prospective, randomized study evaluating the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes

About Agendia

Agendia is a privately held, leading molecular diagnostics company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer and colorectal cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Our offerings include the FDA-cleared MammaPrint® FFPE as well as BluePrint®, a molecular subtyping assay that provides deeper insight leading to more clinically actionable breast cancer biology, and TargetPrint®, a breast cancer ER/PR/HER2 expression assay. These tests can help physicians assess a patient’s individual risk for metastasis – that is, which patients are more sensitive to chemo, hormonal, or combination therapy, and which patients may not require these treatments and which patients may be treated with other, less arduous and costly methods.

In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology. It is also a critical partner in the ISPY-2, NBRST and the MINDACT trials. For more information, visit www.agendia.com.